Adiponectin is associated with improvement of endothelial function after rosiglitazone treatment in non-diabetic individuals with metabolic syndrome

Atherosclerosis

Volumn 195, Issue 1, 2007, Pages 138-146

  Bahia, Luciana ^a   Aguiar, Luiz Guilherme K ^a   Villela, Nivaldo ^a   Bottino, Daniel ^a   Godoy Matos, Amelio F ^b   Geloneze, Bruno ^c   Tambascia, Marcos ^c   Bouskela, Eliete ^a  

^a Institute of Biology Roberto Alcântara Gomes   (Brazil)

^b Instituto Estadual de Diabetes e Endocrinologia Luiz Capriglione   (Brazil)

^c UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Adipokines; Adiponectin; Endothelium; Metabolic syndrome; Rosiglitazone

Indexed keywords

ACETYLCHOLINE; ADIPOCYTOKINE; ADIPONECTIN; C REACTIVE PROTEIN; FIBRINOGEN; NITROPRUSSIDE SODIUM; ROSIGLITAZONE;

ADULT; ARTICLE; BLOOD VESSEL REACTIVITY; CELL FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; DRUG EFFECT; ENDOTHELIUM; FEMALE; FOREARM BLOOD FLOW; HUMAN; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; VASCULAR RESISTANCE; VASODILATATION; VEIN OCCLUSION PLETHYSMOGRAPHY;

ACETYLCHOLINE; ADIPONECTIN; ADULT; C-REACTIVE PROTEIN; ENDOTHELIUM, VASCULAR; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; INSULIN; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NITROPRUSSIDE; THIAZOLIDINEDIONES;

EID: 34248571041     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2006.09.003     Document Type: Article

References (40)

1. Ross R. Mechanisms of disease: atherosclerosis-an inflammatory disease. N Engl J Med 340 (1999) 115-126
2. Davignon J., and Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 109 (2004) III-27-III-32
3. Lerman A., and Zeiher A.M. Endothelial function: cardiac events. Circulation 111 (2005) 363-368
4. Lakka H.M., Laaksonen D.E., and Lakka T.A. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288 (2002) 2706-2716
5. McNeill A.M., Rosamond W.D., Girman C.J., et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diab Care 28 2 (2005) 385-390
6. Hanley A.J., Karter A.J., Williams K., et al. Prediction of type 2 diabetes mellitus with alternative definitions of the metabolic syndrome: the insulin resistance atherosclerosis study. Circulation 112 24 (2005) 3713-3721
7. McVeigh G.E., Brennam G.M., Johnston G.D., et al. Impaired endothelium-dependent and independent vasodilation in patients with type 2 diabetes mellitus. Diabetologia 35 (1992) 771-776
8. Balletshofer B.M., Rittig K., Enderle M.D., et al. Endothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with type 2 diabetes in association with insulin resistance. Circulation 101 15 (2000) 1780-1784
9. Satoh N., Ogawa Y., Usui T., et al. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diab Care 26 (2003) 2493-2499
10. Maeda N., Takahasi M., Finahasi T., et al. PPAR gamma ligants increase expression and plasma concentrations of adiponectin, an adipose derived protein. Diabetes 50 (2001) 2094-2099
11. Pistroch F., Passauer J., Fischer S., et al. In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diab Care 27 (2004) 484-490
12. Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 2002; 106: 3143-421.
13. Chobanian AV, Bakris GL, Black HR, et al. National high blood pressure education program coordinating committee. The seventh report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure: the JNC 7 report. JAMA 2003; 289:2560-72.
14. Matthews D.R., Hosker J.P., Rudenski A.S., et al. Homeostasis model assessment: insulin resistance and beta cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 28 (1985) 412-419
15. Yang W.S., Jeng C.Y., Wu T.J., et al. Synthetic peroxisome proliferator-activated receptor-γ agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diab Care 25 (2002) 376-380
16. Yu J.G., Javorschi S., Hevener A.L., et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese and type2 diabetic subjects. Diabetes 51 (2002) 2968-2974
17. Goldstein B.J., and Scalia R. Adiponectin: a novel adipokine linking adipocytes and vascular function. J Clin Endocrinol Metab 89 (2004) 2563-2568
18. Fernandez-Real J.M., Castro A., Vazquez G., et al. Adiponectin is associated with vascular function independent of insulin sensitivity. Diab Care 27 (2004) 739-745
19. Chen H., Montagnani M., Funahashi T., Shimomura I., and Quon M.J. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem 278 (2003) 45021-45026
20. Shimabukuro M., Higa N., Asahi T., et al. Hypoadiponectinemia is closely linked to endothelial dysfunction in man. J Clin Endocrinol Metab 88 (2003) 3236-3240
21. Weyner C., Funahashi T., Tanaka S., et al. Hipoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86 (2001) 1930-1935
22. Hotta K., Funahashi T., Arita Y., et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20 (2000) 1595-1599
23. Pischon T., Girman C.J., Hotamisligil G.S., et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291 14 (2005) 1730-1737
24. Hartell N.A., Archer H.E., and Bailey C.J. Insulin-stimulated endothelial nitric oxide release is calcium independent and mediated via protein kinase B. Biochem Pharmacol 69 5 (2005) 781-790
25. Martens F.M.A.C., Visseren F.L.J., Koning E.J.P., and Rabelink T.J. Short-term pioglitazone treatment improves vascular function irrespective of metabolic changes in patients with type 2 diabetes. J Cardiovasc Pharmacol 46 (2005) 773-778
26. Wang T.D., Chen W.J., Lin J.W., Chen M.F., and Lee Y.T. Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome. Am J Cardiol 93 (2004) 362-365
27. Hetzel J., Balletshofer B., Rittig K., et al. Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers. Arterioscler Thromb Vasc Biol 25 (2005) 1804-1809
28. Delerive P., Martin-Nizard F., Chinetti G., et al. Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res 85 5 (1999) 394-402
29. Calnek D.S., Mazzella L., Roser S., Roman J., and Hart C.M. Peroxisome proliferator-activated receptor gamma ligands increase release of nitric oxide from endothelial cells. Arterioscler Thromb Vasc Biol 23 1 (2003) 52-57
30. Polikandriotis J.A., Mazzella L.J., Rupnow H.L., and Hart C.M. Peroxisome proliferator-activated receptor gamma ligands stimulate endothelial nitric oxide production through distinct peroxisome proliferator-activated receptor gamma-dependent mechanisms. Arterioscler Thromb Vasc Biol 25 9 (2005) 1810-1816
31. Haffner S.M., Greenberg A.S., Weston W.M., et al. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 106 (2002) 679-684
32. Ruan H., Pownall H.J., and Lodish H.F. Troglitazone antagonizes tumor necrosis factor-alpha-induced reprogramming of adipocyte gene expression by inhibiting the transcriptional regulatory functions of NF-kappaB. J Biol Chem 278 30 (2003) 28181-28192
33. Pasceri V., Wu H.D., Willerson J.T., and Yeh E.T. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation 101 3 (2000) 235-238
34. Carey D.G., Cowin G.J., Galloway G.J., et al. Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients. Obes Res 10 10 (2002) 1008-1015
35. Yusuf S., Hawken S., Ounpuu S., et al. Interheart study investigators obesity and the risk of myocardial infarction in 27000 participants from 52 countries: a case-control study. Lancet 366 9497 (2005) 1640-1649
36. Mayerson A.B., Hundal R.S., Dufour S., et al. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 51 3 (2002) 797-802
37. Buse J.B., Tan M.H., Prince M.J., and Erickson P.P. The effects of oral anti-hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes. Diab Obes Metab 6 2 (2004) 133-156
38. Ovalle F., and Bell D.S. Lipoprotein effects of different thiazolidinediones in clinical practice. Endocr Pract 8 6 (2002) 406-410
39. Tontonoz P., Nagy L., Alvarez J.G., Thomazy V.A., and Evans R.M. PPAR gamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 93 2 (1998) 241-252
40. Chinetti G., Lestavel S., Bocher V., et al. PPAR-alpha PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 7 1 (2001) 53-58